United Therapeutics (UTHR) Competitors $298.20 -4.90 (-1.62%) As of 12:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. ALNY, BIIB, BMRN, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Alnylam Pharmaceuticals Biogen BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations. Is UTHR or ALNY more profitable? United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -12.37%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.31% 19.22% 16.15% Alnylam Pharmaceuticals -12.37%N/A -6.83% Do analysts prefer UTHR or ALNY? United Therapeutics currently has a consensus target price of $390.17, suggesting a potential upside of 30.84%. Alnylam Pharmaceuticals has a consensus target price of $315.58, suggesting a potential upside of 22.11%. Given United Therapeutics' higher possible upside, equities analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Does the media favor UTHR or ALNY? In the previous week, United Therapeutics had 21 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 47 mentions for United Therapeutics and 26 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 1.36 beat Alnylam Pharmaceuticals' score of 0.77 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 26 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable earnings & valuation, UTHR or ALNY? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$2.88B4.65$984.80M$24.6012.12Alnylam Pharmaceuticals$2.25B14.95-$278.16M-$2.17-119.10 Does the MarketBeat Community believe in UTHR or ALNY? Alnylam Pharmaceuticals received 565 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.53% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformUnited TherapeuticsOutperform Votes59962.53% Underperform Votes35937.47% Alnylam PharmaceuticalsOutperform Votes116476.28% Underperform Votes36223.72% Which has more volatility and risk, UTHR or ALNY? United Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Do insiders & institutionals believe in UTHR or ALNY? 94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 11.9% of United Therapeutics shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.41B$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio13.117.3622.6118.58Price / Sales4.65241.71397.51103.15Price / Cash16.6365.8538.1834.62Price / Book2.346.486.704.26Net Income$984.80M$143.43M$3.22B$248.31M7 Day Performance0.60%1.69%1.26%1.34%1 Month Performance-2.83%6.58%3.73%3.92%1 Year Performance16.88%-2.63%15.82%5.33% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9093 of 5 stars$298.20-1.6%$390.17+30.8%+29.3%$13.41B$2.88B13.11980Earnings ReportAnalyst RevisionNews CoveragePositive NewsALNYAlnylam Pharmaceuticals4.2201 of 5 stars$232.75-0.8%$315.58+35.6%+82.9%$30.28B$2.25B-107.262,000Earnings ReportAnalyst DowngradeGap DownBIIBBiogen4.6945 of 5 stars$116.49-1.8%$213.15+83.0%-43.6%$17.05B$9.68B10.418,720Earnings ReportAnalyst DowngradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9278 of 5 stars$58.65-0.9%$94.00+60.3%-21.1%$11.19B$2.85B26.663,080Positive NewsINCYIncyte4.7614 of 5 stars$56.80-2.4%$74.69+31.5%+20.4%$10.99B$4.24B210.382,320Earnings ReportAnalyst ForecastNBIXNeurocrine Biosciences4.8704 of 5 stars$100.68-0.7%$161.86+60.8%-21.7%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionEXELExelixis4.0819 of 5 stars$35.59-1.7%$37.59+5.6%+66.9%$9.96B$2.17B20.111,220Short Interest ↑Analyst RevisionPositive NewsEXASExact Sciences4.4898 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400RGENRepligen4.8598 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageHALOHalozyme Therapeutics4.0007 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.7511 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690Earnings ReportNews CoveragePositive NewsGap Up Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives BMRN Alternatives INCY Alternatives NBIX Alternatives EXEL Alternatives EXAS Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UTHR Stock Free UTHR Stock Alerts